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A candidate gene study of the type I interferon pathway
implicates IKBKE and IL8 as risk loci for SLE
Johanna K Sandling1, Sophie Garnier1,12, Snaevar Sigurdsson1,13, Chuan Wang1, Gunnel Nordmark2,
Iva Gunnarsson3, Elisabet Svenungsson3, Leonid Padyukov3, Gunnar Sturfelt4, Andreas Jo ¨nsen4, Anders
A Bengtsson4, Lennart Truedsson5, Catharina Eriksson6, Solbritt Rantapa ¨a ¨-Dahlqvist7, Anders Ma ¨larstig8,
Rona J Strawbridge8, Anders Hamsten8, Lindsey A Criswell9, Robert R Graham10, Timothy W Behrens10,
Maija-Leena Eloranta2, Gunnar Alm11, Lars Ro ¨nnblom2 and Ann-Christine Syva ¨nen*,1
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease in which the type I interferon pathway has a crucial
role. We have previously shown that three genes in this pathway, IRF5, TYK2 and STAT4, are strongly associated with risk for
SLE. Here, we investigated 78 genes involved in the type I interferon pathway to identify additional SLE susceptibility loci.
First, we genotyped 896 single-nucleotide polymorphisms in these 78 genes and 14 other candidate genes in 482 Swedish SLE
patients and 536 controls. Genes with Po0.01 in the initial screen were then followed up in 344 additional Swedish patients
and 1299 controls. SNPs in the IKBKE, TANK, STAT1, IL8 and TRAF6 genes gave nominal signals of association with SLE in
this extended Swedish cohort. To replicate these ﬁndings we extracted data from a genomewide association study on SLE
performed in a US cohort. Combined analysis of the Swedish and US data, comprising a total of 2136 cases and 9694 controls,
implicates IKBKE and IL8 as SLE susceptibility loci (Pmeta¼0.00010 and Pmeta¼0.00040, respectively). STAT1 was also
associated with SLE in this cohort (Pmeta¼3.3 10 5), but this association signal appears to be dependent of that previously
reported for the neighbouring STAT4 gene. Our study suggests additional genes from the type I interferon system in SLE, and
highlights genes in this pathway for further functional analysis.
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INTRODUCTION
Systemic Lupus Erythematosus (SLE, OMIM 152700) is an inﬂam-
matory autoimmune disease that primarily affects women during their
childbearing years. Production of autoantibodies, tissue deposits of
immune complexes and inﬂammation in kidneys, skin, joints and
central nervous system are hallmarks of SLE. Despite a strong
heritability of the disease, linkage studies have failed to identify
genes outside the major histocompatibility complex (MHC) region
as risk factors for SLE. Association studies have since proven a more
fruitful approach. The conﬁrmed ﬁndings from genomewide associa-
tion studies (GWAS) include genes that were originally discovered in
candidate gene studies, such as the interferon regulatory factor 5
(IRF5)1 and the signal transducer and activator of transcription 4
(STAT4)2 genes from the type I IFN system. IFNs are cytokines with
antiviral activity that are produced in response to viral infections, of
which the type I IFNs bind the IFN-a receptor (IFNAR). Today there
are more than 20 conﬁrmed SLE susceptibility loci,3,4 of which several
are in the type I IFN system.
The type I IFN system is activated in SLE patients,5,6 and an
important role of the type I IFN system in the disease process
was conﬁrmed by studies showing an increased expression of
type I IFN-inducible genes in SLE patients (an ‘IFN-signature’).7
A direct causative role of the type I IFN system in the etiopathogenesis
of SLE was suggested by the observation that individuals treated with
IFN-a can develop an SLE syndrome indistinguishable from the
naturally occurring disease.8 Moreover, a phase I clinical trial with a
monoclonal antibody against IFN-a, reports reduction of disease
activity as well as neutralization of the IFN signature in SLE
patients.9,10 Encouraged by the compelling evidence for the involve-
ment of the type I IFN system in SLE, we performed an association
study to identify additional genes from the type I IFN pathway that
confer risk for SLE.
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Subjects and genotyping
Our study included 826 Swedish and 1310 US SLE patients, fulﬁlling at least
four of the classiﬁcation criteria for SLE as deﬁned by the American College of
Rheumatology (ACR),11 and 9694 healthy control individuals from the same
geographic areas as the patients (Supplementary Table S1). DNA was extracted
from blood samples of the patients and controls using standard procedures.
The study was approved by the regional ethical boards and all subjects gave
their informed consent to participate. The study was performed in three stages:
Discovery phase. First, a panel of SNPs in 82 genes with key functions related
to the type I IFN signalling system and 14 additional genes, with suggested
association with SLE, were selected for genotyping in 490 Swedish SLE patients
and 543 controls. Patients were from the rheumatology clinics at the Lund,
Karolinska (Solna) and Uppsala University Hospitals in Sweden. SNPs were
selected on the basis of their average spacing of around 1kb and LD
information from the HapMap project (r2o0.8 HapMap CEU release 16c),
excluding SNPs with an Illumina quality score o0.6. Genotyping of 1258 SNPs
in the 96 genes was performed using the Golden Gate Assay (Illumina Inc., San
Diego, CA, USA). Samples and SNPs with 410% missing data, SNPs with
Hardy–Weinberg equilibrium test P-values o0.001 and SNPs with MAF o0.01
were excluded from further analysis. Four parent–offspring trios were included
in the genotyping for inheritance checks, and no Mendelian inheritance errors
were observed. After exclusion of genetic outliers, duplicate or related samples
482 cases, 536 controls and 896 SNPs in 92 genes were available for analysis.
Conﬁrmatory set. In the second phase, SNPs in the eight most promising
genes were followed up in 393 patients and 1645 controls from Sweden.
Patients were from the rheumatology clinics at the Umea ˚, Uppsala and
Karolinska (Solna) University Hospitals. For the patients and 972 of the
controls, genotyping of 25 SNPs was performed using the 12-plex and 48-plex
SNPStream systems12 (Beckman Coulter Inc., Brea, CA, USA). Primer
sequences are provided in Supplementary Table S2. The same quality control
ﬁlters as for the discovery cohort were applied, and samples overlapping with
the discovery phase were excluded. Additional Swedish population-based
controls from the Stockholm area (n¼673), previously genotyped using the
Inﬁnium II assay on human 1M v1 bead arrays13 (Illumina Inc.), were also
included after applying the following quality ﬁlters: MAF41%, HWE
P41 10 6,S N Pa n ds a m p l ec a l lr a t e s495%. After exclusion of genetic
outliers, duplicate or related samples, a total of 344 cases, 1299 controls and 21
SNPs were available for analysis.
GWAS. We sought replication of our results by using data from a GWAS on
SLE in US Caucasians.14 In brief, 1435 North-American SLE cases of European
descent and 3583 controls had been genotyped on HumanHap550 bead arrays
(Illumina Inc.). An additional 4564 controls were also included as previously
described.4 After strict quality control14 1310 cases and 7859 controls remained.
Additional quality control and imputation
For the 673 Swedish controls genotyped on the 1M bead arrays, genotypes for
13 conﬁrmatory phase SNPs that were not directly genotyped were imputed
using the software IMPUTE and phasing data from the HapMap project.15 In
the US GWAS dataset genotypes were imputed for 15 SNPs using the IMPUTE
software. SNPs had imputation conﬁdence scores Z0.90 with one exception
(rs4694178, conﬁdence 0.85 in the US data). For all the Swedish SLE patients,
and for more than half of the Swedish controls genotyped using the
GoldenGate or SNPstream methods, data from 6060 uncorrelated ancestry
informative markers (AIMs) became available during the course of our study.4
Using this data, genetic outliers were identiﬁed with principal component
analysis by the EIGENSTRATsoftware16 and excluded from the study (the ten
ﬁrst principal components were inferred and a cut-off of s46 was used to
identify outliers). These samples were also checked for cryptic relatedness by
investigation of identity-by-state (IBS) status in PLINK17 (http://pngu.mgh.
harvard.edu/purcell/plink/) using a set of 12k previously genotyped SNPs. For
the Swedish controls, genotyped on the 1M arrays, all markers were used to
identify cryptically related samples and 6035 successfully genotyped AIMs were
used to identify genetic outliers.
Association analysis and power calculation
The association analysis of the directly genotyped SNPs was performed by
comparing allele frequencies in cases and controls with Fisher’s exact or Chi2
tests using PLINK. A null distribution for the quantile–quantile (Q–Q) plot
was generated with PLINK and plotted using R (http://www.r-project.org/).
Analyses including imputed genotypes were performed using SNPTEST,15
which takes imputation uncertainty into account. SNPs, which were not
captured by imputation were only analysed in the directly genotyped samples.
Conditional logistic regression analysis assuming an additive model was
performed using PLINK to test for independence of association signals
observed in neighbouring genes, or between associated SNPs within the same
gene. Tests for pairwise SNP interactions were performed using the epistasis
command in PLINK. The combined analysis of the Swedish and US case-
control data was performed using the software Metal (http://www.sph.umich.
edu/csg/abecasis/Metal/index.html). Pooled odds ratios were calculated using
the Mantel–Haenszel method under a ﬁxed effects model, and tests for
heterogeneity of odds ratios between studies were calculated using the MedCalc
software (http://www.medcalc.be/). Power calculations were performed using
the software QUANTO (http://hydra.usc.edu/GxE/) assuming a log-additive
model, and a prevalence for SLE in Sweden of 0.05%.
RESULTS
We selected a panel of SNPs in 78 genes with key functions related to
the type I IFN signalling system to study their association with SLE in
a Swedish case-control cohort. The selected genes encode Toll-like
receptors (TLRs) and intracellular sensor molecules for nucleic
acids (ie RIG-I-like receptors: RLR) and members of their signalling
pathways, including several transcription factors that are active in the
IFN producing pDCs and membrane proteins of the pDCs. Genes
encoding the members of the type I IFN family and other genes
regulated by the TLRs that are involved in the response to the type I
and type III IFNs, and genes for which the expression is directly
regulated by type I IFNs, were also included in the panel. Although
the type I and type III IFNs bind two different receptors, the IFNAR
and IFN-l receptor, they share downstream signalling and
IFN-l-induced genes are also induced by type I IFNs. A total of 14
additional genes that are not directly involved in the type I IFN
system, but have been suggested to be associated with SLE were also
included (Supplementary Table S3). This analysis identiﬁed 21 SNPs
in seven genes that yielded unadjusted P-values o0.01: IKBKE, TANK,
STAT1, IL8, NRP1, TRAF6 and PIAS4 (Figure 1 and Supplementary
Table S3). At this signiﬁcance level only nine associated SNPs would be
expected to yield association signals by chance, which indicates
the presence of true association signals in our data (Supplementary
Figure S1). The power for the discovery phase, which included 482
SLE cases and 536 controls, was 65% to detect an OR of 1.5 at 0.01
signiﬁcance for a 10% frequency allele. However, our power to detect
genes with an OR of 1.2 was considerably lower (10%), and thus we
cannot exclude that genes, which remained undetected in our study
may contribute to the risk for SLE.
To increase power, we designed a panel of SNPs in the IKBKE,
TANK, STAT1, IL8, NRP1, TRAF6 and PIAS4 genes for genotyping
in an independent collection of Swedish SLE patients and controls.
The STAT5B gene was also included in the follow-up study, as initially
one SNP in the gene showed a P-value o0.01. This was, however,
before an additional quality control step, by which related samples
and population outliers were excluded. For genes, where multiple
SNPs showed P-values o0.05 in the discovery phase, candidate
SNPs for follow-up were tested for independence of their association
signal in relation to the most strongly associated SNP in each gene
(Supplementary Table S4). A partly redundant set of 21 SNPs that
accounted for the association signals from the discovery phase was
then analysed in the second Swedish case-control cohort. Also in this
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the data from the Swedish discovery and conﬁrmatory cohorts,
totalling 826 cases and 1835 controls, we observed strong association
signals with Po5 10 4 for the SNPs rs2030171 in STAT1 and
rs4694178 in IL8 (Table 1 and Supplementary Table S5). Multiple
linked SNPs in the TRAF family member-associated NFkB activator
(TANK) and TNF receptor-associated factor 6 (TRAF6)g e n e sa l s o
gave suggestive signals of association with SLE in the combined
Swedish cohort. In addition, two weakly correlated SNPs in
the IKBKE gene (rs1539243 and rs17433930, LD r2¼0.34) displayed
P-values o0.05. Conditional regression analysis did not provide
evidence for more than one allele contributing to risk for SLE in
genes with multiple associated SNPs (Supplementary Table S5), nor
was there any evidence for epistatic interactions between SNPs at
different loci.
We sought independent replication of our results by using data
from a GWAS on SLE in European Americans.14 The SNPs, rs1539243
and rs17433930, in the IKBKE gene showed signals of association with
SLE also in the US data (P¼0.0028 and P¼0.0021, respectively)
(Table 2 and Supplementary Table S6). The SNP rs1539243 had
been directly genotyped in the US cohort, and for rs17433930 imputed
genotypes were analysed. Combined analysis of the data from the
Swedish and US cohorts revealed convincing association signals with
SLE for these SNPs (Pmeta¼0.00026, OR¼1.19, and Pmeta¼0.00010,
OR¼1.33, for rs1539243 and rs17433930, respectively), a result which
was signiﬁcant also after Bonferroni correction (Pmeta_corro0.01). The
two IKBKE SNPs rs17433930 and rs1539243, which we found to be
associated with SLE are located in the tenth intron and fourth exon of
the gene, respectively, where rs1539243 is a synonymous SNP in
amino-acid residue 67 (Ile) of the IKKe kinase.
Although the SNP rs4694178, located 3.3kb downstream of the IL8
gene, had only a trend-wise signiﬁcant P-value in the US cohort
compared with the more convincing association with SLE in the
Swedish cohort (PUS¼0.064, PSWE¼5 10 5), its association signal
remained signiﬁcant in the combined analysis after Bonferroni
correction (Pmeta¼0.00040, OR¼1.17, Pmeta_corro0.01) (Table 2).
This SNP was imputed in the US data (conﬁdence¼0.85), however,
the directly genotyped SNP rs9999446, which is strongly correlated
with the SNP rs4694178 (r2¼0.86) yielded a similar result (P¼0.085)
for association with SLE. For the SNP rs10199181 in the STAT1
gene, we observed combined P-values o1 10 3.T h eSTAT1 gene
is located close to the STAT4 gene in a region of high LD on
chromosome 2q32.2. STAT4 contains two linked SNPs, rs10181656
and rs7582694, which are strongly associated with SLE,18 and
Table 1 Combined analysis of association with SLE in the Swedish discovery and conﬁrmation cohortsa
Gene CHR SNP b Basepair Minor/major alleles MAF cases MAF controls P c Risk allele OR (95% CI)
IKBKE 1 rs1539243 204714410 T/C 0.16 0.18 0.031 C 1.19 (1.02–1.39)
IKBKE 1 rs17433930 204719362 G/A 0.07 0.09 0.013 A 1.33 (1.06–1.67)
TANK 2 rs3754974 161721201 G/A 0.05 0.04 0.0087 G 1.44 (1.09–1.89)
TANK 2 rs1267075 161768063 G/A 0.19 0.18 0.75 G 1.02 (0.88–1.19)
STAT1 2 rs2030171 191577408 A/G 0.35 0.29 1.2E 05 A 1.31 (1.16–1.49)
STAT1 2 rs16833172 191584314 A/G 0.04 0.03 0.015 A 1.51 (1.09–2.09)
IL8 4 rs4694178 74831552 C/A 0.52 0.46 5.2E 05 C 1.26 (1.12–1.42)
NRP1 10 rs734187 33524702 A/G 0.24 0.24 0.67 A 1.03 (0.90–1.18)
NRP1 10 rs1331314 33564687 G/C 0.11 0.10 0.32 G 1.11 (0.92–1.34)
NRP1 10 rs2073320 33593263 A/G 0.38 0.37 0.42 A 1.05 (0.93–1.18)
TRAF6 11 rs5030482 36466602 C/T 0.12 0.14 0.0094 T 1.25 (1.05–1.49)
TRAF6 11 rs5030472 36470362 T/C 0.09 0.12 0.013 C 1.28 (1.05–1.55)
STAT5B 17 rs6503691 37647616 T/C 0.09 0.10 0.44 C 1.08 (0.88–1.32)
PIAS4 19 rs2289863 3979783 C/T 0.27 0.29 0.19 T 1.09 (0.96–1.25)
Abbreviations: CI, conﬁdence Interval; MAF, minor Allele Frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.
a826 Swedish cases and 1835 controls genotyped in the discovery and replication phases including controls genotyped on the 1M chip.
bGenotypes for rs17433930, rs3754974, rs2030171, rs16833172, rs4694178, rs734187 and rs1331314 were imputed in the Swedish controls genotyped on the 1M chip.
cP-values calculated using SNPtest.
P-values o0.05 are indicated in bold.
Figure 1 Association with SLE for the 92 genes tested in the discovery phase (482 Swedish cases and 536 controls). The negative logarithm of the P-value
from a w2- test is plotted against chromosomal location. The grey line represents P¼0.05, and the black line P¼0.01.
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cohort indicates that the association signals from the STAT1 and
STAT4 SNPs are not independent of each other (data not shown,
remaining Pconditional40.3).
DISCUSSION
Our association study of genes from the type I IFN pathway and
additional candidate genes for SLE highlighted two genes, IKBKE and
IL8, as potential risk factors for SLE. In addition, the genes TRAF6 and
TANK showed signiﬁcant association with SLE in the Swedish cohorts.
Furthermore, IRF5, TYK2, STAT4, IFIH1, IRAK1, IRF8 and the
PHRF1/IRF7 region have been reported by us elsewhere to be
associated with SLE.1,4,18 Thus, polymorphisms in multiple genes
connected to the type I IFN signalling system are important for SLE
disease susceptibility.
IKBKE, the inhibitor of nuclear factor kappa-B kinase subunit
epsilon gene, encodes IKKe, a kinase that together with the TANK-
binding kinase (TBK1) has a role in the innate antiviral response.
IKKe and TBK1 are activated when two intracellular RLR helicases,
encoded by the IFIH1 and DDX58 genes, recognise viral RNA in
virus-infected cells (Figure 2). These kinases are also activated upon
stimulation of endosomal TLR3 by double stranded DNA, or cell
membrane TLR4 by bacterial lipopolysaccharide (LPS). Together with
TBK1, IKKe mediates phosphorylation of the transcription factors
IRF3 and IRF7, which leads to their activation and subsequent
transcription of type I IFN and other inﬂammatory cytokines, but
also activation of NFkB has been reported.19,20 The activation of IRF3
and IRF7 can be inhibited by an ubiquitin-editing enzyme (A20),
encoded by the TNFAIP3 gene. As also variation in TNFAIP3 and
IFIH1 are associated with SLE,4,21,22 this further supports an impor-
tant role for the RLR pathway in the disease process. There is also
evidence that IKKe can phosphorylate STAT1, and thus contribute to
the type I IFN signalling through the IFNAR.23
The IKBKE gene has recently been implicated in risk for rheuma-
toid arthritis (RA).24 The two polymorphisms with the most signiﬁ-
cant association with RA were tested in the discovery phase of our
study (rs2151222 and rs3748022 with P¼0.084 and P¼0.49 for
association to SLE, respectively), however, these variants appear to
be independent from the IKBKE variants rs1539243 and rs17433930
that we identiﬁed as risk alleles for SLE (r2o0.1 discovery phase). The
conjecture that IKBKE has a role in arthritis is supported by data from
an animal model. IKKe knockout mice have been shown to be less
sensitive to induction of arthritis and exhibit less joint destruction
than control mice.25 In a published GWAS on women with SLE26 the
IKBKE SNP rs1539243 was tested, but no association was observed
(dbGaP, http://www.ncbi.nlm.nih.gov/gap). The power of that study
was, however, only 23% at the P¼0.05 level to detect the association
we observe.
The chemokine IL-8 has a wide range of pro-inﬂammatory effects,
and its production can be triggered by immune complexes that also
have the capacity to induce type I IFN production.27 Recent data also
suggests that IL-8 production in virus-infected cells is IFN depen-
dant.28 SLE patients with renal29 or CNS involvement30 have elevated
IL-8 levels in their serum and cerebrospinal ﬂuid, respectively, and
serum IL-8 levels and disease activity correlate in SLE patients.31 As
SLE disease ﬂares are associated with increased IFN-a production,6
these observations provide a link between the SLE disease process, IL-8
and the type I IFN system.
Although we observed a signiﬁcant association of IL8 with SLE in
this study, there are previous conﬂicting reports on the association
between IL8 and SLE,26,32–34 only two of which, a Spanish case-control
study and a GWAS in women with SLE, having similar power to our
discovery phase. The power of these studies was around 50% at the
0.05 signiﬁcance level to detect the effect for IL8 that we observe. The
LD between the SNP rs2227306 tested in the Spanish study and the
SNP rs4694178 in our study is very high (r2¼0.97 in the HapMap
CEU population), but they do not observe any association with
SLE for this SNP.34 In our study, the association signal is mainly
contributed by the Swedish cohort, which has a higher frequency of
the risk allele than both the US and Spanish cohorts (control
frequency of rs4694178 C: Sweden¼0.46, USA¼0.41 and the linked
allele rs2227306 T: Spain¼0.41). In the women GWAS,26 aS N P
Table 2 Meta-analysis of association with SLE for the Swedish and US cohorts
Sweden a US b Meta-analysis c
Gene SNP P d OR (95% CI) P d OR (95% CI) e Risk allele P Corrected P f OR (95% CI) e
IKBKE rs1539243 0.031 1.19 (1.02–1.39) 0.0028 1.20 (1.07–1.35) C 0.00026 0.0054 1.19 (1.09–1.31)
IKBKE rs17433930 0.013 1.33 (1.06–1.67) 0.0021 1.33 (1.11–1.58) A 0.00010 0.0022 1.33 (1.16–1.53)
TANK rs3754974 0.0087 1.44 (1.09–1.89) 0.98 0.99 (0.80–1.22) NA 0.22 1.0 1.13 (0.96–1.34)
TANK rs1267075 0.75 1.02 (0.88–1.19) 0.87 0.99 (0.89–1.11) NA 0.99 1.0 1.00 (0.92–1.10)
STAT1 rs2030171 1.2E 05 1.31 (1.16–1.49) 0.018 1.11 (1.02–1.21) A 3.3E 05 0.00069 1.17 (1.09–1.26)
STAT1 rs16833172 0.015 1.51 (1.09–2.09) 0.16 1.23 (0.95–1.59) A 0.016 0.34 1.33 (1.09–1.63)
IL8 rs4694178 5.2E 05 1.26 (1.12–1.42) 0.064 1.13 (1.04–1.23) C 0.00040 0.0084 1.17 (1.10–1.26)
NRP1 rs734187 0.67 1.03 (0.90–1.18) 0.66 1.01 (0.92–1.12) A 0.56 1.0 1.02 (0.94–1.10)
NRP1 rs1331314 0.32 1.11 (0.92–1.34) 0.11 1.11 (0.97–1.26) G 0.061 1.0 1.11 (1.00–1.23)
NRP1 rs2073320 0.42 1.05 (0.93–1.18) 0.61 0.98 (0.90–1.06) NA 0.94 1.0 1.00 (0.94–1.07)
TRAF6 rs5030482 0.0094 1.25 (1.05–1.49) 0.12 1.10 (0.97–1.24) T 0.0097 0.20 1.14 (1.03–1.26)
TRAF6 rs5030472 0.013 1.28 (1.05–1.55) 0.19 1.09 (0.96–1.25) C 0.020 0.42 1.15 (1.03–1.28)
STAT5B rs6503691 0.44 1.08 (0.88–1.32) 0.78 0.98 (0.86–1.12) NA 0.91 1.0 1.01 (0.90–1.13)
PIAS4 rs2289863 0.19 1.09 (0.96–1.25) 0.72 0.98 (0.89–1.08) NA 0.76 1.0 1.02 (0.95–1.10)
Abbreviations: CI, conﬁdence Interval; MAF, minor Allele Frequency; NA, not Available; OR, odds ratio; SNP, single-nucleotide polymorphism.
a826 Swedish cases and 1835 controls genotyped in the discovery and replication phases including controls genotyped on the 1M chip.
b1310 US SLE cases and 7859 controls genotyped in a GWAS. Genotypes for rs17433930, rs3754974, rs2030171, rs16833172, rs4694178, rs734187, rs1331314 and rs5030482 were
imputed in this dataset as described in Gateva et al.
cMeta-analysis including 2136 SLE cases and 9694 controls.
dP-values calculated using SNPtest.
eOdds ratios are calculated relative to the risk allele deﬁned in the analysis of the combined Swedish cohort.
fP-value corrected for the 21 tested SNPs.
P-values o0.05 are indicated in bold.
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CEU) was tested, and showed an odds ratio suggestive of association
with SLE (OR CI: 1.01–1.49, dbGaP). The modest power to detect an
effect of this size, or genetic heterogeneity between populations could
explain these conﬂicting results.
Although the TANK and TRAF6 genes, which gave clear association
signals (Po0.001) in the Swedish cohort, did not replicate in the
US GWAS data, these genes remain interesting candidates. TANK
signals immediately upstream of IKKe in the TLR4- and IFIH1/
DDX58-mediated activation of type I IFNs and inﬂammatory
cytokines in response to bacterial and viral stimuli, respectively
(Figure 2). Association of TANK with SLE would thus further
support an important role for the RLR pathway in SLE. TRAF6 is a
ubiquitin ligase that mediates signal transduction from, for example,
members of the TLR family leading to activation of NFkB and IRFs.
Polyubiquitination of IRF5 after its interaction with IRAK1 is
mediated by TRAF6, which enables IRF5 to translocate to the nucleus
and exert its effect on gene expression. On the other hand, TNFAIP3
can inhibit TLR-induced activity of NFkB by de-ubiquitination of
TRAF6.35 Interestingly, also IRAK1 has been associated with risk for
SLE,36 and because SNPs in the TRAF6 region and in TNFAIP3 have
also been associated with risk for RA,37–39 it seems as variants of all
these genes have the potential to contribute to loss of tolerance and
autoimmune reactions. Further studies will be needed to determine
whether the TANK and TRAF6 genes have an effect on SLE, and
whether this effect is speciﬁc for Scandinavian populations.
Our study conﬁrms the important role of the type I IFN system in
SLE, and suggests multiple genes from this pathway as candidates for
functional studies and as interesting therapeutic targets (Figure 2).
These results also point more speciﬁcally to the importance of genes in
the RLR pathway, which is activated in response to viral infections
because of the ability of IFIH1/DDX58 to recognise cytoplasmic
viral RNA. This pathway is active in cells other than the pDCs,
including monocyte derived dendritic cells. In addition to IFIH1,
factors such as TANK, IKBKE and TNFAIP3 contribute to signalling
in the RLR pathway (reviewed in 40) .H o w e v e r ,t h e r ei sa l s oe v i d e n c ef o r
involvement in SLE of the MYD88-dependent pathway activated by
endosomal TLR7/9 by RNA/DNA from dying cells, immune complexes
Figure 2 A schematic illustration of signalling within the type I interferon (IFN) system. Circled gene names have conﬁrmed association to SLE: STAT4,
IRF5, IRF7, IRF8, TNFAIP3 (A20),T N F S F 4(OX40L), FCGR2A, TYK2, IFIH1 (MDA5), IRAK1,a sw e l la sIKBKE and IL8, identiﬁed in this study. Genes with
dashed circles are TANK and TRAF6, which we ﬁnd associated with SLE in the Swedish but not US cohorts, and STAT1 that has an association signal,
which cannot be distinguished from that of STAT4. Left: Induction of inﬂammatory cytokines and type I IFN genes in response to viral RNA/DNA by the
helicases IFIH1 (MDA5), DDX58 (RIG-I) and the DNA sensor ZBP1 (DAI), or by bacterial LPS through toll-like receptor 4. These pathways signal using TANK
that interacts with IKBKE or TBK1, which together can mediate phosphorylation of the interferon regulatory factors IRF3 and 7, leading to the transcription
of type I IFN genes. Activation of this pathway can be inhibited by TNFAIP3 (A20). Middle: Induction of IFN production in plasmacytoid dendritic cells
(pDCs) by endogenous immune complexes. Immune complexes are endocytosed through FCGRIIA, which leads to activation of TLR7/9. After a signalling
cascade, which includes IRAK1 and TRAF6, the interferon regulatory factors IRF5 and IRF7 are activated leading to the transcription of type I IFN genes.
Also IRF8 can contribute to this activation. Right: IFN signalling through the type I IFN receptor IFNAR. Association of type I IFN to the receptor activates
the kinases TYK2 and JAK1, which signal through STAT1 and STAT2. Also other STATs, including STAT4, are activated in this process. The STAT1/STAT2
complex associates with IRF9, which in turn binds to interferon-stimulated response elements (ISREs) and induces expression of IFN-induced genes, such
as IRF5, IRF7 and indirectly IL8. Far right: Membrane proteins expressed on pDCs. TNFSF4 (OX40L), together with endogenous type I IFNs provide a
means for the pDCs to control the T-cell response, speciﬁcally to proﬁle it towards a TH1 response. Activation of the NFkB pathway, and thus production of
inﬂammatory cytokines, also occurs through TLR7/9 (not shown). Proteins are denoted by their corresponding gene names.
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potentially TRAF6, in this pathway are associated with SLE. Thus, at
least two pathways seem important in SLE, both leading to production
of type I IFN and inﬂammatory cytokines through activation of IRF3,
IRF5 and IRF7, and additional transcriptions factors, especially NFkB.
Association to SLE has further been demonstrated for the type I IFN
signalling through the IFNAR, speciﬁcally for TYK2 and STAT4,a sw e l l
as the IFN-regulated genes IFIH1, IRF5, IRF7 and IL8.C o n s e q u e n t l y ,a
large number of genes, located in different functional parts of the type I
IFN system, are associated with SLE indicating a general role for the
type I IFN system genes in autoimmunity.
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